Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

306 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomised, placebo-controlled extension study.
Menzies-Gow A, Wechsler ME, Brightling CE, Korn S, Corren J, Israel E, Chupp G, Bednarczyk A, Ponnarambil S, Caveney S, Almqvist G, Gołąbek M, Simonsson L, Lawson K, Bowen K, Colice G; DESTINATION study investigators. Menzies-Gow A, et al. Among authors: korn s. Lancet Respir Med. 2023 May;11(5):425-438. doi: 10.1016/S2213-2600(22)00492-1. Epub 2023 Jan 23. Lancet Respir Med. 2023. PMID: 36702146 Clinical Trial.
Inhaled anti-TSLP antibody fragment, ecleralimab, blocks responses to allergen in mild asthma.
Gauvreau GM, Hohlfeld JM, FitzGerald JM, Boulet LP, Cockcroft DW, Davis BE, Korn S, Kornmann O, Leigh R, Mayers I, Watz H, Grant SS, Jain M, Cabanski M, Pertel PE, Jones I, Lecot JR, Cao H, O'Byrne PM. Gauvreau GM, et al. Among authors: korn s. Eur Respir J. 2023 Mar 9;61(3):2201193. doi: 10.1183/13993003.01193-2022. Print 2023 Mar. Eur Respir J. 2023. PMID: 36822634 Free PMC article. Clinical Trial.
Efficacy of Tezepelumab in Severe, Uncontrolled Asthma: Pooled Analysis of the PATHWAY and NAVIGATOR Clinical Trials.
Corren J, Menzies-Gow A, Chupp G, Israel E, Korn S, Cook B, Ambrose CS, Hellqvist Å, Roseti SL, Molfino NA, Llanos JP, Martin N, Bowen K, Griffiths JM, Parnes JR, Colice G. Corren J, et al. Among authors: korn s. Am J Respir Crit Care Med. 2023 Jul 1;208(1):13-24. doi: 10.1164/rccm.202210-2005OC. Am J Respir Crit Care Med. 2023. PMID: 37015033 Free PMC article. Clinical Trial.
Reply to Lipworth and Chan.
Ambrose CS, Israel E, Bowen K, Llanos JP, Martin N, Cook B, Hellqvist Å, Korn S, Menzies-Gow A, Roseti SL, Molfino NA, Griffiths JM, Parnes JR. Ambrose CS, et al. Among authors: korn s. Am J Respir Crit Care Med. 2023 Jul 15;208(2):212-213. doi: 10.1164/rccm.202305-0843LE. Am J Respir Crit Care Med. 2023. PMID: 37279366 Free PMC article. No abstract available.
Response to Biologics and Clinical Remission in the Adult German Asthma Net Severe Asthma Registry Cohort.
Milger K, Suhling H, Skowasch D, Holtdirk A, Kneidinger N, Behr J, Timmermann H, Schulz C, Schmidt O, Ehmann R, Hamelmann E, Idzko M, Taube C, Lommatzsch M, Buhl R, Korn S. Milger K, et al. Among authors: korn s. J Allergy Clin Immunol Pract. 2023 Sep;11(9):2701-2712.e2. doi: 10.1016/j.jaip.2023.05.047. Epub 2023 Jun 8. J Allergy Clin Immunol Pract. 2023. PMID: 37301433 Free article.
Characterization of Obesity in Severe Asthma in the German Asthma Net.
Bal C, Pohl W, Milger K, Skowasch D, Schulz C, Gappa M, Koerner-Rettberg C, Jandl M, Schmidt O, Zehetmayer S, Taube C, Hamelmann E, Buhl R, Korn S, Idzko M; German Asthma Net (GAN) study group. Bal C, et al. Among authors: korn s. J Allergy Clin Immunol Pract. 2023 Nov;11(11):3417-3424.e3. doi: 10.1016/j.jaip.2023.06.049. Epub 2023 Jul 4. J Allergy Clin Immunol Pract. 2023. PMID: 37406803
Characterization of Austrian severe asthma patients.
Renner A, Stoshikj S, Pohl W, Bal C, Reisinger M, Löffler-Ragg J, Zacharasiewicz A, Buhl R, Hamelmann E, Taube C, Korn S, Idzko M. Renner A, et al. Among authors: korn s. Respir Med. 2023 Nov-Dec;219:107427. doi: 10.1016/j.rmed.2023.107427. Epub 2023 Oct 10. Respir Med. 2023. PMID: 37827294 Free article.
Reduction of daily maintenance inhaled corticosteroids in patients with severe eosinophilic asthma treated with benralizumab (SHAMAL): a randomised, multicentre, open-label, phase 4 study.
Jackson DJ, Heaney LG, Humbert M, Kent BD, Shavit A, Hiljemark L, Olinger L, Cohen D, Menzies-Gow A, Korn S; SHAMAL Investigators. Jackson DJ, et al. Among authors: korn s. Lancet. 2024 Jan 20;403(10423):271-281. doi: 10.1016/S0140-6736(23)02284-5. Epub 2023 Dec 7. Lancet. 2024. PMID: 38071986 Free article. Clinical Trial.
306 results